Margaret Pfeiffer, MD
Ophthalmic Plastic and Reconstructive Surgery · Dallas, TXNPI 1679816862
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,278 of the $4,278 with a category attached, or 76.6%. Amgen accounts for 77.4% of it on its own, with 8 other manufacturers making up the rest.
Across 64 payments — averaging $66.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Merz Pharmaceuticals, LLC$230
- Kerecis Limited$171
- Eyevance Pharmaceuticals LLC$163
- Biotissue Holdings Inc.$153
- Bausch & Lomb Americas Inc.$140
- plus $108 from 3 others
What the payments were for
- Consulting fees$1,00023%
- Food & beverage$3,27877%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 46 | $3,313 |
| Merz Pharmaceuticals, LLC | 8 | $230 |
| Kerecis Limited | 1 | $171 |
| Eyevance Pharmaceuticals LLC | 2 | $163 |
| Biotissue Holdings Inc. | 1 | $153 |
| Bausch & Lomb Americas Inc. | 2 | $140 |
| AbbVie | 2 | $64 |
| Tarsus Pharmaceuticals, Inc. | 1 | $28 |
| Harrow Eye, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$2,384
- Kerecis Omega3 Marigen$684
- Kerecis Omega3 SurgiClose$171
- Prokera$153
- AmnioGraft$153
- Zerviate$147
- IC-8 Apthera IOL$125
- enVista MX60 IOL$125
How this compares
$4,278 in reported general payments places this provider in the 70th percentile of 36 ophthalmic plastic and reconstructive surgery providers in Texas.
See all ophthalmic plastic and reconstructive surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 444 | $4,926 |
| Prednisolone Acetate | 27 | $1,510 |
| ErythromycinErythromycin Base | 76 | $892 |
| Tramadol Hcl | 186 | $281 |
| Ofloxacin | 24 | $252 |
| Doxycycline Hyclate | 14 | $169 |
| Methylprednisolone | 13 | $93 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Dallas
- Helen MerrittDallas$4K
- Jorge CoronaDallas$3K
- James MerrittDallas$3K
- Meredith AbbottDallas$3K
- Kamel ItaniDallas$2K
- Phillip TenzelDallas$937
- Pooja ParikhDallas$534
- Vikram DurairajAustin$379K
- David GayDripping Springs$93K
- Richard AllenAustin$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.